ClinicalTrials.gg
WithdrawnNCT01547312Updated Oct 14, 2015

Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)

A Phase 1 interventional study of Peg-Interferon and Liver Samples from FNA in Chronic Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-10-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
36th of 39
0 · median 99
Started
2012
with 2 others
Phase 1
4 of 40
none open now
Registered
34th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 36th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2012, is one of 4 in phase 1, and was the 34th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

This study is divided into 2 segments, and proposes to qualify fine needle aspiration (FNA) as a platform to evaluate the hepatic pharmacokinetics of low and high oral doses of Grazoprevir (MK-5172) in non-cirrhotic participants chronically infected with hepatitis C virus (HCV). The first segment, is a procedural pilot conducted prior to the main study, that is aimed at ensuring optimal execution of the FNA procedure. During the procedural pilot, core needle biopsy (CNB) will be performed on participants as part of their standard of care, but no study drugs will be administered, nor will any procedures other than FNA be conducted. The second segment, the main study, is designed to evaluate the feasibility of measuring Grazoprevir by FNA. During the main study, drugs will be administered, and other additional procedures will be conducted.

03

Conditions studied

  • Chronic Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has chronic compensated infection.
  • No to CNB or FNA procedures.
  • Pilot study only: All comers with chronic HCV already scheduled to undergo CNB for fibrosis staging.
  • Pilot study only: Requires a diagnostic liver to monitor progression of liver disease.
  • Pilot study only: Does not have cirrhosis.
  • Main study only: Males or non-pregnant and females willing to use medically acceptable during, and for 6 months or longer after study.
  • Main study only: of 18.5 - 32.0 kg/m\^2.
  • Main study only: Can avoid aspirin, anticoagulants, and non steroidal inflammatory agents.
  • Main study only: Has undergone prior treatment or is treatment naive for chronic HCV infection.

Exclusion criteria

Exclusion Criteria for Main study only:

  • History of any of the following: stroke, chronic seizures, major neurological disorders, gastric bypass surgery or bowel resection.
  • No viral response to prior interferon based therapy.
  • Prior treatment for with an NS3/4A protease inhibitor.
  • History of either , uncontrolled endocrine, gastrointestinal, cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities/diseases.
  • History of neoplastic or myeloproliferative disease.
  • Has any of the following : cirrhosis, decompensated liver disease, or other advanced liver disease, hepatocellular carcinoma, infection with (HIV), or .
  • Evidence of high grade bridging fibrosis from prior liver or chronic hepatitis not caused by HCV.
  • History of illicit drug use or alcohol abuse.
  • Had surgery, donated at least one unit of blood, or participated in any other study within 4 weeks prior to screening visit.
  • History of multiple and/or severe allergies.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV

    800 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.

    Drug: Peg-Interferon · Procedure: Liver Samples from FNA · Procedure: Liver Samples from CNB · Procedure: Blood Samples · Drug: Ribavirin · Drug: 800 mg Grazoprevir

  • Experimental
    Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV

    100 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.

    Drug: Peg-Interferon · Procedure: Liver Samples from FNA · Procedure: Liver Samples from CNB · Procedure: Blood Samples · Drug: Ribavirin · Drug: 100 mg Grazoprevir

  • Experimental
    Main Pt.1: 800 mg Grazoprevir

    800 mg Grazoprevir.

    Procedure: Liver Samples from FNA · Procedure: Liver Samples from CNB · Procedure: Blood Samples · Drug: 800 mg Grazoprevir

  • Experimental
    Procedural Pilot

    Optimization of FNA procedure.

    Procedure: Liver samples from CNB and FNA

Interventions

  • Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.

    Also known as: PegIntron

  • ProcedureLiver Samples from FNA

    Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.

  • ProcedureLiver Samples from CNB

    Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.

  • ProcedureBlood Samples

    Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.

  • Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.

    Also known as: Rebetol

  • 800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.

  • 100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.

  • ProcedureLiver samples from CNB and FNA

    Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.

06

What researchers measure

Primary outcomes

  1. Number of participants from whom detectable concentrations of hepatic Grazoprevir are obtained by FNA.

    Time frame: Days 7-12.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2012
First posted
Mar 7, 2012
Start
May 2012
Primary completionEst.
Nov 2012
CompletionEst.
Nov 2012
Last update
Oct 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01547312
Responsible party
Sponsor
First posted
Mar 7, 2012
Start date
May 2012
Primary completion
Nov 2012 (estimated)
Completion
Nov 2012 (estimated)
Last update
Oct 14, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin · Grazoprevir

Start the discussion